Description: Mirati Therapeutics Inc., a biopharmaceutical company, engages in the development of therapeutics for the cancer treatment. Its lead program in clinical development is MGCD265, a multi-targeted small molecule kinase inhibitor for treatment of oncology patients with solid tumors. The company also evaluates development opportunities in oncology for mocetinostat, a spectrum-selective HDAC inhibitor for the treatment of patients with myelodysplastic syndrome or lymphoma; and MGCD516, a kinase inhibitor with a target profile for the treatment of patients with non-small cell lung cancer and other solid tumors. Mirati Therapeutics Inc. is headquartered in San Diego, California.
Home Page: www.mirati.com
MRTX Technical Analysis
3545 Cray Court
San Diego,
CA
92121
United States
Phone:
858 332 3410
Officers
| Name | Title |
|---|---|
| Mr. David D. Meek | CEO & Director |
| Dr. Charles M. Baum M.D., Ph.D. | Founder, Pres, Head of R&D and Director |
| Dr. James G. Christensen Ph.D. | Exec. VP & Chief Scientific Officer |
| Mr. Benjamin J. Hickey M.B.A. | Chief Commercial Officer |
| Ms. Laurie D. Stelzer | Chief Financial Officer |
| Ms. Reena R. Desai | Chief Legal Officer & Corp. Sec. |
| Mr. Michael E. Paolucci | Chief People Officer |
| Dr. Kelly Covello Ph.D. | VP & Head of Medical Affairs |
| Mr. Ryan Asay | VP & Head of Corp. Affairs |
| Dr. Alan Bart Sandler M.D. | Exec. VP & Chief Medical Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.1294 |
| Price-to-Sales TTM: | 207.5881 |
| IPO Date: | 2004-06-29 |
| Fiscal Year End: | December |
| Full Time Employees: | 413 |